Net zero transition to mean significant change for 1.3 million workers

The UK’s experience of structural change through deindustrialisation during the 1970s and 1980s drove up unemployment, concentrated among particular parts of the population, and left deep scars on some parts of the country. However, the net zero transition will have impact on jobs across the economy but is unlikely to follow the same path as these previous episodes of change. Molly Broome, Stefano Cellini, Kathleen Henehan, Charlie McCurdy, Capucine Riom, Anna Valero, and Guglielmo Ventura assess the likely scale – and nature – of labour market change brought on by the net zero transition over the next decade

The 2020s will be a crunch decade that will determine the UK’s trajectory into the mid-21st century

As vaccines roll out and restrictions are lifted, public debate is turning to the economic recovery from COVID-19 and the deepest annual downturn for 300 years that came in its wake. But viewing the years ahead simply as the post-pandemic period is far too limited a frame, say the authors of the Economy 2020 Inquiry. Instead, the 2020s look set to be the decisive decade during which the UK will need to renew its approach to achieving economic success

Creating science-driven computer architecture: A new path to scientific leadership

This document proposes a multi-site strategy for creating a new class of computing capability for the U.S. by undertaking the research and development necessary to build supercomputers optimized for science in partnership with the American computer industry

Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.

Purpose: To evaluate the efficacy of the aromatase inhibitor letrozole in preselected estrogen receptor (ER)–positive relapsed epithelial ovarian cancer patients and to identify markers that predict endocrine-sensitive disease. Experimental Design: This was a phase II study of letrozole 2.5 mg daily until clinical or marker evidence of disease progression in previously treated ER-positive ovarian cancer patients with a rising CA125 that had progressed according to Rustin's criteria. The primary end point was response according to CA125 and response evaluation criteria in solid tumors (RECIST) criteria. Marker expression was measured by semiquantitative immunohistochemistry in sections from the primary tumor. Results: Of 42 patients evaluable for CA125 response, 7 (17%) had a response (decrease of >50%), and 11 (26%) patients had not progressed (doubling of CA125) following 6 months on treatment. The median time taken to achieve the CA125 nadir was 13 weeks (range 10-36). Of 33 patients evaluable for radiological response, 3 (9%) had a partial remission, and 14 (42%) had stable disease at 12 weeks. Eleven patients (26%) had a PFS of >6 months. Subgroup analysis according to ER revealed CA125 response rates of 0% (immunoscore, 150-199), 12% (200-249), and 33% (250-300); P = 0.028, χ2 for trend. Expression levels of HER2, insulin-like growth factor binding protein 5, trefoil factor 1, and vimentin were associated with CA125 changes on treatment. Conclusions: This is the first study of a hormonal agent in a preselected group of ER-positive ovarian cancer patients. A signature of predictive markers, including low HER2 expression, predicts response